Redeye shares its initial take on Stille's Q3 2026 results. Sales were slightly below our estimates, while EBIT exceeded expectations. Surgical Instruments continued to deliver strong organic growth, partly supported by the fulfilment of previous backorders, while Surgical Tables maintained solid momentum. Cash flow also improved significantly during the quarter.
LÄS MER
